Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL31411333 | 0.91 | SLC6A2 (0.35) | KDM4EALDH1A1 | |
| SCHEMBL31411305 | 0.87 | HTR1A (0.43) | HTR1AKDM4EALDH1A1HTR2A | |
| SCHEMBL31411332 | 0.84 | ALDH1A1 (0.36) | HTR1AKDM4EALDH1A1HTR2A | |
| SCHEMBL31411312 | 0.81 | HTR1A (0.45) | HTR1AHTR2A | |
| Fumaric Acid SCHEMBL31411436 | 0.78 | NPSR1 (0.37) | HTR1AKDM4EALDH1A1HTR2A | |
| SCHEMBL31411330 | 0.78 | HTR1A (0.30) | HTR1AHTR2A | |
| SCHEMBL25748542 | 0.77 | HTR1A (0.51) | HTR1AKDM4EALDH1A1HTR2A | |
| SCHEMBL30483731 | 0.77 | HTR1A (0.51) | HTR1AKDM4EALDH1A1HTR2A | |
| SCHEMBL31411401 | 0.76 | MAPK1 (0.32) | HTR1A | |
| SCHEMBL31411411 | 0.74 | HTR2A (0.37) | ALDH1A1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735425-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2026-05-06 | — | — | EP | disclosed |
| US-20250353818-A1 | Compounds | Psylo Pty Ltd (AU) | 2025-11-20 | — | — | US | disclosed |
| US-12428380-B2 | Compounds | Psylo Pty Ltd (AU) | 2025-09-30 | — | — | US | disclosed |
| US-20250214943-A1 | Compounds | Psylo Pty Ltd (AU) | 2025-07-03 | — | — | US | disclosed |
| WO-2025000053-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-01-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214943-A1 | Compounds | NLN, SLC18A2, PYGB | HTR1A 185/4885KDM4E 3243/4885ALDH1A1 981/4885 |
| US-12428380-B2 | Compounds | NLN, SLC18A2, PYGB | HTR1A 185/4885KDM4E 3243/4885ALDH1A1 981/4885 |
| US-20250353818-A1 | Compounds | NLN, SLC18A2, PYGB | HTR1A 185/4885KDM4E 3243/4885ALDH1A1 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.